Intellia’s Lonvo-z Meets HAELO Phase 3 Secondary Endpoints in HAE
Rare Disease & Gene Therapy — June 15, 2026
Intellia’s one-time CRISPR therapy lonvoguran ziclumeran (lonvo-z) met its HAELO Phase 3 secondary endpoints in hereditary angioedema — published simultaneously in the New England Journal of Medicine — while Rocket Pharmaceuticals banked $180 million from selling a rare-disease priority review voucher.
Today’s top developments:
- Intellia’s lonvoguran ziclumeran (lonvo-z) met its secondary endpoints in the HAELO Phase 3 trial in hereditary angioedema, with the manuscript published simultaneously in the New England Journal of Medicine and presented at EAACI 2026 (Fierce Biotech)
- Rocket Pharmaceuticals sold a rare disease priority review voucher for $180 million, a non-dilutive transaction that extends its cash position as its lentiviral and AAV gene therapy programs advance (MedCity News)
- A MedCity News analysis examined what it takes for rare disease developers to access FDA expedited pathways — Breakthrough Therapy, RMAT, and accelerated approval — where RMAT plus rolling review can compress timelines by six to nine months (MedCity News)
What to Watch
- Intellia lonvo-z NDA timeline — Intellia is expected to announce a lonvo-z NDA submission timeline following HAELO data consolidation. Long-term durability data beyond 12 months will be the central variable for payer negotiations and formulary positioning in HAE prophylaxis.
- Rocket’s $180M deployment — How Rocket Pharma deploys the PRV proceeds — toward LAD-I or Fanconi anemia commercial infrastructure versus further pipeline investment — will signal its near-term priority programs.
- PRV program policy risk — PRV secondary-market pricing at $180M raises the question of whether Congressional proposals to restrict or sunset the rare pediatric disease voucher program will affect developer financing models over the next 12 to 24 months.
- FDA surrogate endpoint guidance — FDA surrogate endpoint guidance updates for ultra-rare conditions with sub-200-patient trial populations remain an open variable that could materially affect Phase 2-to-NDA timelines for multiple gene therapy programs in 2026 and 2027.
This brief highlights today’s top stories. Read the full June 15, 2026 edition → for all stories, source links, and analysis.
